Archer Materials Limited, an Australian semiconductor company that specializes in quantum technology and medical diagnostics, recently shared a significant update. The company successfully fabricated its advanced Biochip graphene field effect transistor (gFET) design on a six-inch wafer. This is a major milestone in transitioning from research to commercial-scale production.
The fabrication process was carried out in collaboration with Graphenea, a Spanish partner, and resulted in the production of 145 chips. Each chip contained 8 gFET devices that demonstrated the expected electronic performance and device stability, indicating a successful production run. This achievement showcases Archer’s commitment to enhancing its Biochip technology, with plans to develop further miniaturized designs currently in progress.
Investors looking for more information on AU:AXE stock can visit TipRanks’ Stock Analysis page for additional insights and analysis. Archer Materials Limited continues to make strides in the semiconductor industry, solidifying its position as a leader in quantum technology and medical diagnostics.
